SCHEMBL3018738

SCHEMBL3018738

Cc1cc(C)c(-c2csc(N3CCN(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
TSHR P16473 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
ALOX15 P16050 1/20 0.45
MAPT P10636 5/20 0.44
USP2 O75604 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 4/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPK1 P28482 2/20 0.43
AR P10275 1/20 0.43
NPSR1 Q6W5P4 3/20 0.42
ALDH3A1 P30838 1/20 0.42
CNR1 P21554 1/20 0.41
HTT P42858 1/20 0.41
PKM P14618 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
RECQL P46063 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3000574 0.92 ALDH1A1 (0.47) ALDH1A1TSHRL3MBTL1ALOX15MAPT
SCHEMBL3009661 0.92 AR (0.45) ALDH1A1TSHRL3MBTL1MAPTUSP2
SCHEMBL3015989 0.89 ALDH1A1 (0.53) ALDH1A1TSHRMAPTUSP2LMNA
SCHEMBL3009220 0.89 KMT2A (0.50) ALDH1A1L3MBTL1MAPTUSP2SMN1; SMN2
SCHEMBL3020343 0.89 SMN1; SMN2 (0.49) ALDH1A1TSHRL3MBTL1ALOX15MAPT
SCHEMBL3013014 0.88 ALDH1A1 (0.43) ALDH1A1L3MBTL1MAPTUSP2SMN1; SMN2
SCHEMBL3014730 0.88 SMN1; SMN2 (0.55) ALDH1A1TSHRL3MBTL1MAPTUSP2
SCHEMBL3007484 0.88 MEN1 (0.50) ALDH1A1TSHRL3MBTL1MAPTUSP2
SCHEMBL3015951 0.87 SMN1; SMN2 (0.41) ALDH1A1TSHRMAPTSMN1; SMN2LMNA
SCHEMBL3019901 0.87 SMN1; SMN2 (0.54) ALDH1A1TSHRL3MBTL1ALOX15MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885TSHR 3320/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.